48 /100
MEDIUM RISK
Score updated Jul 14, 2026

JBIO — Jade Biosciences, Inc. Dilution Risk Tracker

Track JBIO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track JBIO — Get alerts when the score changes →

As of July 14, 2026, Jade Biosciences, Inc. (JBIO) has a DilutionWatch DilutionScore of 48/100, rated MEDIUM dilution risk. Jade Biosciences, Inc. has a market capitalization of $1.04B, 49.36M shares outstanding, 122 institutional holders tracked. Key dilution vectors include approximately 66 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
66
💰 Cash Runway
0
📊 Float Risk
35
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
7%
🔁 Convertible Conversion 15%
• Convertible debt present: 9.1% potential dilution
🔔 Track JBIO — Get forecast alerts →

💹 Market Data

Market Cap$1.04B
Shares Outstanding49.36M
Float32.74M
Cash$311.30M
Debt$849.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 23.5% shares (2026Q1 vs prior)
122 institutional holders · 58.64M shares
#1 FMR LLC 7.09M shares
#2 JANUS HENDERSON GROUP PLC 6.21M shares
#3 Fairmount Funds Management LLC 4.55M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest8.15M
Days to Cover4.8
% of Float24.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for JBIO Shareholders

Jade Biosciences, Inc. (JBIO) has a DilutionScore of 48/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for JBIO shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for JBIO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for JBIO alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track JBIO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking JBIO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for JBIO
📊 JBIO FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 JBIO Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.